Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PPIA | P62937 | 11/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29273709 | 0.83 | MAPT (0.65) | KMT2AMEN1LMNAPPIAMAPT | |
| SCHEMBL22873283 | 0.80 | KMT2A (0.61) | KMT2AMEN1LMNAPPIAMAPT | |
| SCHEMBL16593178 | 0.77 | KMT2A (0.56) | KMT2AMEN1LMNAPPIAMAPT | |
| SCHEMBL13480594 | 0.76 | PPIA (0.61) | KMT2AMEN1LMNAPPIAMAPT | |
| SCHEMBL144326 | 0.76 | KMT2A (0.65) | KMT2AMEN1LMNAPPIAMAPT | |
| SCHEMBL13969504 | 0.74 | KMT2A (0.53) | KMT2AMEN1LMNAPPIAMAPT | |
| SCHEMBL16592358 | 0.74 | CA12 (0.63) | KMT2AMEN1PPIAMAPTTSHR | |
| SCHEMBL1567605 | 0.74 | KMT2A (0.61) | KMT2AMEN1LMNAPPIAMAPT | |
| SCHEMBL1007576 | 0.74 | MAPT (0.62) | KMT2AMEN1LMNAPPIAMAPT | |
| SCHEMBL27817518 | 0.73 | NTRK1 (0.59) | KMT2AMEN1LMNAPPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718782-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718782-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGF, NGFR, NTRK2 | KMT2A 4196/4885MEN1 4769/4885LMNA 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.